These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24628539)

  • 1. Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis.
    Czaja AJ
    Aliment Pharmacol Ther; 2014 May; 39(10):1043-58. PubMed ID: 24628539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.
    Czaja AJ
    Aliment Pharmacol Ther; 2014 Feb; 39(4):385-406. PubMed ID: 24387318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis.
    Czaja AJ; Carpenter HA
    Liver Int; 2003 Apr; 23(2):116-23. PubMed ID: 12654134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal.
    Czaja AJ
    Dig Dis Sci; 2010 Jun; 55(6):1761-9. PubMed ID: 20428945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Withdrawal in Autoimmune Hepatitis.
    Bouma G; van Nieuwkerk CM
    Dig Dis; 2015; 33 Suppl 2():88-93. PubMed ID: 26641661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: reversibility of hepatic fibrosis and immunosuppression withdrawal in patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome.
    Yilmaz B; Dayanan R
    Aliment Pharmacol Ther; 2015 Apr; 41(8):794. PubMed ID: 25781049
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: reversibility of hepatic fibrosis and immunosuppression withdrawal in patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome - author's reply.
    Czaja AJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):794-5. PubMed ID: 25781048
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term treatment reduction and steroids withdrawal in children with autoimmune hepatitis: a single centre experience on 55 children.
    Dumortier J; Arita CT; Rivet C; LeGall C; Bouvier R; Fabien N; Guillaud O; Collardeau-Frachon S; Scoazec JY; Lachaux A
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1413-8. PubMed ID: 19907227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of treatment withdrawal in type 1 autoimmune hepatitis.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Liver Int; 2007 May; 27(4):507-15. PubMed ID: 17403191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly.
    Chen J; Eslick GD; Weltman M
    Aliment Pharmacol Ther; 2014 Jan; 39(2):117-24. PubMed ID: 24261965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2233-6. PubMed ID: 21839242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy in the management of type 1 autoimmune hepatitis.
    Czaja AJ
    Drugs; 1999 Jan; 57(1):49-68. PubMed ID: 9951951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.
    Kanzler S; Löhr H; Gerken G; Galle PR; Lohse AW
    Z Gastroenterol; 2001 May; 39(5):339-41, 344-8. PubMed ID: 11413913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
    Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
    Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difficult treatment decisions in autoimmune hepatitis.
    Czaja AJ
    World J Gastroenterol; 2010 Feb; 16(8):934-47. PubMed ID: 20180231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the current treatment of autoimmune hepatitis.
    Czaja AJ
    Dig Dis Sci; 2012 Aug; 57(8):1996-2010. PubMed ID: 22476586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Am J Gastroenterol; 2007 May; 102(5):1005-12. PubMed ID: 17319926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis.
    Hartl J; Ehlken H; Weiler-Normann C; Sebode M; Kreuels B; Pannicke N; Zenouzi R; Glaubke C; Lohse AW; Schramm C
    J Hepatol; 2015 Mar; 62(3):642-6. PubMed ID: 25457202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis.
    Purnak T; Efe C; Kav T; Wahlin S; Ozaslan E
    Dig Dis Sci; 2017 Oct; 62(10):2900-2907. PubMed ID: 28871464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.